Zai Lab (ZLAB) Return on Capital Employed (2021 - 2026)
Zai Lab (ZLAB) posted quarterly Return on Capital Employed of 32.72% for Q1 2026, down 154.0% year-on-year from 60.6% in Q1 2025, and down 6.9% on a QoQ basis from 30.61% in Q4 2025.
Zai Lab (ZLAB) Return on Capital Employed (2021 - 2026) Analysis & Trends
Zai Lab (ZLAB) has reported Return on Capital Employed for 6 consecutive years, with 32.72% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed fell 154.0% year-over-year to 32.72% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32.72% (down 154.0% YoY) and the FY2025 annual result came in at 30.07%, up 469.0% from the prior year.
- Return on Capital Employed fell to 32.72% in Q1 2026 per ZLAB's latest filing, from 30.61% in the prior quarter.
- Over the last five years, Return on Capital Employed for ZLAB reached as high as 28.43% in Q3 2025 and fell as low as 48.31% in Q3 2024.
- A 5-year average of 37.69% and a median of 36.81% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed slumped 1254 bps — and 2025, when it surged 1988 bps.
- Year by year, Return on Capital Employed stood at 36.12% in 2022, then slipped by 21 bps to 43.8% in 2023, then climbed by 18 bps to 35.89% in 2024, then rose by 15 bps to 30.61% in 2025, then declined by 7 bps to 32.72% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 32.72%, 30.61%, and 28.43% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Zai Lab | 22.02 Bn | 22.02 Bn | 61.30 Mn | -32.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.72% |
| Dec 31, 2025 | -30.61% |
| Sep 30, 2025 | -28.43% |
| Jun 30, 2025 | -29.50% |
| Mar 31, 2025 | -31.19% |
| Dec 31, 2024 | -35.89% |
| Sep 30, 2024 | -48.31% |
| Jun 30, 2024 | -48.08% |
| Mar 31, 2024 | -44.79% |
| Dec 31, 2023 | -43.80% |
| Sep 30, 2023 | -35.77% |
| Jun 30, 2023 | -38.30% |
| Mar 31, 2023 | -36.81% |
| Dec 31, 2022 | -36.12% |
| Sep 30, 2022 | -43.74% |
| Jun 30, 2022 | -37.25% |
| Mar 31, 2022 | -39.47% |
| Dec 31, 2021 | -47.43% |
| Sep 30, 2021 | -33.90% |
| Jun 30, 2021 | -43.14% |